Insulet Stock Forecast, Price & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 48.0% and is now trading at $254.75.
View which stocks have been most impacted by COVID-19.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Insulet a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Insulet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) released its earnings results on Wednesday, November, 4th. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.09. The medical instruments supplier earned $234 million during the quarter, compared to analyst estimates of $221.73 million. Insulet had a return on equity of 10.96% and a net margin of 2.20%. The firm's quarterly revenue was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $885.84-893.222 million, compared to the consensus revenue estimate of $874.11 million.

18 brokerages have issued 1 year price objectives for Insulet's stock. Their forecasts range from $179.00 to $266.00. On average, they expect Insulet's stock price to reach $235.19 in the next twelve months. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (1.43%), Federated Hermes Inc. (0.53%), Standard Life Aberdeen plc (0.52%), Charles Schwab Investment Management Inc. (0.49%), KAMES CAPITAL plc (0.45%) and Victory Capital Management Inc. (0.43%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., First Trust Advisors LP, Wasatch Advisors Inc., Commerce Bank, Perceptive Advisors LLC, WINTON GROUP Ltd, Trexquant Investment LP, and ClariVest Asset Management LLC. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Jennison Associates LLC, Parian Global Management LP, Standard Life Aberdeen plc, British Airways Pensions Investment Management Ltd, AXA S.A., William Blair Investment Management LLC, and Employees Retirement System of Texas.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $254.75.

Insulet has a market capitalization of $16.80 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]